{
    "clinical_study": {
        "@rank": "92404", 
        "arm_group": {
            "arm_group_label": "TAU-284", 
            "arm_group_type": "Experimental", 
            "description": "Two TAU-284 5mg tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed)."
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to evaluate the long-term safety and efficacy of TAU-284\n      (Bepotastine besilate) in pediatric patients with perennial allergic rhinitis for 12 weeks\n      administration."
        }, 
        "brief_title": "A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Perennial Allergic Rhinitis", 
        "condition_browse": {
            "mesh_term": [
                "Rhinitis", 
                "Rhinitis, Allergic, Perennial"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a multicenter,open-label, single-arm, uncontrolled study to evaluate the safety and\n      efficacy of TAU-284 (20 mg/day) in pediatric patients with perennial allergic rhinitis for\n      12 weeks administration."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged between 7 and 15 years\n\n          -  Patients who have received a diagnosis of perennial allergic rhinitis according to\n             the diagnostic criteria\n\n          -  Patients with a mean total score for the three major nasal symptoms [sneezing,\n             rhinorrhea, and nasal congestion] of at least 3 on the basis of symptoms recorded in\n             the nasal allergy diary during the observation period  etc.\n\n        Exclusion Criteria:\n\n          -  Patients with vasomotor rhinitis or eosinophilic rhinitis\n\n          -  Patients who have concurrent nasal disease that may affect the efficacy of TAU-284\n\n          -  Patients with a history of any of the nasal surgical procedures\n\n          -  Patients with current or previous history of drug allergy\n\n          -  Patients who concurrently have renal function abnormalities that may cause safety\n             problems  etc."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "15 Years", 
            "minimum_age": "7 Years"
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01900054", 
            "org_study_id": "TAU-284-18"
        }, 
        "intervention": {
            "arm_group_label": "TAU-284", 
            "description": "Two TAU-284 5mg tablets will be taken orally twice a day", 
            "intervention_name": "Bepotastine besilate", 
            "intervention_type": "Drug", 
            "other_name": "TALION 5mg tablets"
        }, 
        "intervention_browse": {
            "mesh_term": "Histamine H1 Antagonists"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "TAU-284", 
            "Bepotastine besilate", 
            "Histamine H1 receptor antagonists", 
            "children"
        ], 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kanagawa", 
                    "country": "Japan"
                }, 
                "name": "Reserch site"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "overall_official": {
            "affiliation": "Nippon Medical School", 
            "last_name": "KIMIHIRO OKUBO", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Adverse events and adverse drug reactions", 
            "safety_issue": "Yes", 
            "time_frame": "Up to Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01900054"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in total score for the three major nasal symptoms [sneezing, rhinorrhea, and nasal congestion]", 
                "safety_issue": "No", 
                "time_frame": "baseline, Week2, Week4, Week6, Week8, Week10, Week 12 and final evaluation point"
            }, 
            {
                "measure": "Change from baseline in individual nasal symptom scores (sneezing, rhinorrhea, nasal congestion, and impairment in daily activities)", 
                "safety_issue": "No", 
                "time_frame": "baseline, Week2, Week4, Week6, Week8, Week10 and Week 12"
            }, 
            {
                "measure": "Change from baseline in individual scores for local nasal findings (rhinoscopic findings)", 
                "safety_issue": "No", 
                "time_frame": "Second enrollment, Week2, Week4, Week6, Week8, Week10 and Week 12"
            }, 
            {
                "measure": "Change from baseline in severity score for symptoms of allergic rhinitis", 
                "safety_issue": "No", 
                "time_frame": "baseline, Week2, Week4, Week6, Week8, Week10 and Week 12"
            }, 
            {
                "measure": "Influence of activities in daily life(study, outing, sleeping)", 
                "safety_issue": "No", 
                "time_frame": "Second enrollment, Week2, Week4, Week6, Week8, Week10 and Week 12"
            }, 
            {
                "measure": "Patient impression of nasal symptoms(sneezing, rhinorrhea, nasal congestion, nasal pruritus, eye pruritus and eye tearing)", 
                "safety_issue": "No", 
                "time_frame": "Week 12 or suspension"
            }
        ], 
        "source": "Mitsubishi Tanabe Pharma Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mitsubishi Tanabe Pharma Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}